Related Experiment Video
Updated: Sep 13, 2025
07:05
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
9.0K
Ashwa.30: A Bioactive-Optimized Ashwagandha Extract for Clinically Validated Low-Dose Efficacy
Alternative Therapies in Health and Medicine
|July 31, 2025
Summary
Ashwa.30, a novel Withania somnifera extract, demonstrates efficacy at a low 30 mg/day dose. This clinically validated formulation enhances endurance, stress resilience, and well-being through optimized bioactive compounds.
Area of Science:
- Integrative and Functional Health
- Phytochemistry
- Pharmacology
Background:
- Conventional Withania somnifera extracts often require high dosages for efficacy.
- There is a need for standardized, low-dose botanical formulations with demonstrated clinical benefits.
Purpose of the Study:
- To introduce Ashwa.30, a novel, dual-standardized Withania somnifera extract.
- To elucidate the scientific rationale, development, and advantages of Ashwa.30 for health applications.
Main Methods:
- Development utilizing Bioactive Optimization Technology (B.O.T.).
- Dual-standardization of withanolides and a proprietary ATP-active fraction.
- Summary of preclinical and clinical study findings.
Main Results:
- Ashwa.30 achieves efficacy at a significantly lower dose (30 mg/day) compared to conventional products.
- Demonstrated improvements in endurance, stress resilience, and overall well-being in clinical studies.
- Synergistic action of optimized withanolides and ATP-active fraction.
Conclusions:
- Ashwa.30 represents a next-generation solution for integrative and functional health.
- The low-dose, high-efficacy profile offers a distinct advantage in botanical supplementation.
- Further research supports its role in enhancing physiological resilience and performance.
More Related Videos
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.6K
10:33Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
1.4K
Related Concept Videos
01:22Dose-Response Relationship: Potency and Efficacy
5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
01:13Therapeutic Index
5.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
5.1K
01:13Bioavailability: Overview
3.1K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.1K
01:03Dose-Response Relationship: Overview
3.7K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.7K
01:26Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K